Goldman Sachs invests in Aragen Life Sciences for significant minority stake Goldman Sachs Goldman Sachs on Wednesday said it has made an investment in Aragen Life Sciences for a significant minority stake in the contract research organization. It, however, did not disclose the value of the investment. Goldman Sachs's alternative investing arm Goldman Sachs Asset Management picked up shares in the company, which was earlier known as GVK Biosciences, from Chryscapital and other investors, as per an official statement. A media report on Monday had said Chryscapital will be selling its 17 percent and promoters will dilute 16 percent to give one-third ownership of the company to Goldman, and the total company valuation was pegged at $1 billion.